Search research articles
Contact Us
Filters
Showing results (1-10 of 51) with videos related to
Page
of 6
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 9, 2004
Drug interactions in gastroenterology: mechanisms, consequences, and how to avoid
Laurence J Egan
Journal of Crohn'S & Colitis
|
September 9, 2017
Ten Years of the Journal of Crohn's and Colitis
Laurence J Egan
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 14, 2007
A nudge in the right direction: shaping the metabolic fate of thiopurines for therapeutic gain
Laurence J Egan
Inflammatory Bowel Diseases
|
June 5, 2007
Allopurinol and 6MP: steering through the therapeutic obstacle course
Laurence J Egan
Digestive Diseases (Basel, Switzerland)
|
July 8, 2011
Mechanisms of drug toxicity or intolerance
Laurence J Egan
Carcinogenesis
|
January 12, 2012
Inflammation, DNA methylation and colitis-associated cancer
Lori Hartnett, Laurence J Egan
Annals of the New York Academy of Sciences
|
October 24, 2006
NF-kappaB signaling: pros and cons of altering NF-kappaB as a therapeutic approach
Laurence J Egan, Murat Toruner
Gut
|
January 2, 2014
Taking a closer look at IBD
Laurence J Egan, William Sandborn
Current Gastroenterology Reports
|
November 30, 2005
Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis
Laurence J Egan, William J Sandborn
Inflammatory Bowel Diseases
|
September 9, 2015
New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor-α Monoclonal Antibodies in Inflammatory Bowel Disease
Stephanie M Slevin, Laurence J Egan
Page
of 6
Search research articles
Search
Showing results (1-10 of 51) with videos related to
Sort By:
Page
of 6
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 9, 2004
Drug interactions in gastroenterology: mechanisms, consequences, and how to avoid
Laurence J Egan
Journal of Crohn'S & Colitis
|
September 9, 2017
Ten Years of the Journal of Crohn's and Colitis
Laurence J Egan
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 14, 2007
A nudge in the right direction: shaping the metabolic fate of thiopurines for therapeutic gain
Laurence J Egan
Inflammatory Bowel Diseases
|
June 5, 2007
Allopurinol and 6MP: steering through the therapeutic obstacle course
Laurence J Egan
Digestive Diseases (Basel, Switzerland)
|
July 8, 2011
Mechanisms of drug toxicity or intolerance
Laurence J Egan
Carcinogenesis
|
January 12, 2012
Inflammation, DNA methylation and colitis-associated cancer
Lori Hartnett, Laurence J Egan
Annals of the New York Academy of Sciences
|
October 24, 2006
NF-kappaB signaling: pros and cons of altering NF-kappaB as a therapeutic approach
Laurence J Egan, Murat Toruner
Gut
|
January 2, 2014
Taking a closer look at IBD
Laurence J Egan, William Sandborn
Current Gastroenterology Reports
|
November 30, 2005
Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis
Laurence J Egan, William J Sandborn
Inflammatory Bowel Diseases
|
September 9, 2015
New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor-α Monoclonal Antibodies in Inflammatory Bowel Disease
Stephanie M Slevin, Laurence J Egan
Page
of 6